Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case–control study
Open Access
- 28 November 2014
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 1-8
Abstract
Pregnant women with a history of acquired thrombotic thrombocytopenic purpura (TTP) are considered at risk for disease recurrence and might be at risk for miscarriage, similar to other autoimmune disorders. However, the exact entity of these risks and their causes are unknown. The aim of this study was to evaluate risk factors associated with adverse pregnancy outcome, in terms of both gravidic TTP and miscarriage, in women affected by previous acquired TTP. We conducted a nested case–control study in women with a history of acquired TTP enrolled in the Milan TTP registry from 1994 to October 2012, with strict inclusion criteria to reduce referral and selection bias. Fifteen out of 254 women with acquired TTP were included, namely four cases with gravidic TTP, five with miscarriage, and six controls with uncomplicated pregnancy. In the cases, ADAMTS13 activity levels in the first trimester were moderately-to-severely reduced (median levels <3% in gravidic TTP and median levels 20% [range 14-40%] in the women with miscarriage) and anti-ADAMTS13 antibodies were invariably present, while in the control group ADAMTS13 activity levels were normal (median 90%, range 40-129%), with absence of detectable anti-ADAMTS13 antibodies. Reduced levels of ADAMTS13 activity (<25%) in the first trimester were associated with an over 2.9-fold increased risk for gravidic TTP and with an over 1.2-fold increased risk for miscarriage (lower boundary of the confidence interval of the odds ratio). In addition, the presence of anti-ADAMTS13 antibodies during pregnancy was associated with an over 6.6-fold increased risk for gravidic TTP and with an over 4.1-fold increased risk for miscarriage. ADAMTS13 activity evaluation and detection of anti-ADAMTS13 antibody could help to predict the risk of complications in pregnant women with a history of acquired TTP.Keywords
This publication has 27 references indexed in Scilit:
- Successful management of pregnancy‐associated thrombotic thrombocytopenic purpura by monitoring ADAMTS13 activityJournal of Obstetrics and Gynaecology Research, 2012
- ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancyBritish Journal of Haematology, 2011
- Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathiesThrombosis and Haemostasis, 2011
- Pathophysiology of thrombotic thrombocytopenic purpuraInternational Journal of Hematology, 2010
- Pregnancy‐induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw–Schulman syndrome: a series of 15 pregnancies in 9 genotyped patientsBritish Journal of Haematology, 2009
- Thrombotic Thrombocytopenic Purpura: A Thrombotic Disorder Caused by ADAMTS13 DeficiencyHematology/Oncology Clinics of North America, 2007
- Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpuraBlood Coagulation & Fibrinolysis, 2006
- Thrombotic thrombocytopenic purpura and its diagnosisJournal of Thrombosis and Haemostasis, 2005
- von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery womenThrombosis and Haemostasis, 2004
- Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnanciesEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2003